GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)
India
· Delayed Price · Currency is INR 2,543.10
+33.80 (1.35%)
At close: Dec 5, 2025
BOM:500660 Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Net Income | 9,553 | 9,276 | 5,900 | 6,107 | 16,947 | 3,581 | Upgrade
|
| Depreciation & Amortization | 562.5 | 565.7 | 591.43 | 560.73 | 587.16 | 695.71 | Upgrade
|
| Other Amortization | 102.22 | 102.22 | 105.37 | 96.94 | 94.7 | 90.34 | Upgrade
|
| Loss (Gain) From Sale of Assets | 13.93 | 15.13 | -8.89 | -0.28 | -3.24 | 0.59 | Upgrade
|
| Loss (Gain) From Sale of Investments | -772.6 | -696.5 | -487.76 | -307.79 | -5.92 | - | Upgrade
|
| Provision & Write-off of Bad Debts | 16.56 | 23.76 | 5.87 | -73.64 | 1.62 | 20.61 | Upgrade
|
| Other Operating Activities | -78.85 | 1,765 | -895.67 | -1,124 | -11,442 | -38.93 | Upgrade
|
| Change in Accounts Receivable | -662.98 | -728.68 | -302.69 | 202.28 | 102.04 | -999.34 | Upgrade
|
| Change in Inventory | -183.09 | 433.11 | -650.78 | 747.25 | 120.03 | -467.93 | Upgrade
|
| Change in Accounts Payable | -1,505 | 769.69 | 1,901 | -1,532 | 1,024 | 1,074 | Upgrade
|
| Change in Other Net Operating Assets | 387.86 | 1,374 | -337.69 | 125.16 | -47.1 | 850.63 | Upgrade
|
| Operating Cash Flow | 7,433 | 12,899 | 5,820 | 4,842 | 8,107 | 5,779 | Upgrade
|
| Operating Cash Flow Growth | -23.47% | 121.63% | 20.20% | -40.27% | 40.29% | 17.82% | Upgrade
|
| Capital Expenditures | -242.22 | -230.22 | -312.22 | -440.39 | -346.41 | -442.27 | Upgrade
|
| Sale of Property, Plant & Equipment | 207.47 | 57.17 | 224.56 | 14.57 | 11.77 | 1,807 | Upgrade
|
| Sale (Purchase) of Real Estate | - | - | - | 97.8 | 323.42 | 18.41 | Upgrade
|
| Investment in Securities | 3,634 | -1,444 | -1,454 | 9,563 | -18,124 | 2,250 | Upgrade
|
| Other Investing Activities | 1,264 | 1,159 | 1,629 | -1,156 | 14,080 | 547.26 | Upgrade
|
| Investing Cash Flow | 4,864 | -458.01 | 87.12 | 8,079 | -4,055 | 4,180 | Upgrade
|
| Long-Term Debt Repaid | - | -187.31 | -181.25 | -168.68 | -156.18 | -149.84 | Upgrade
|
| Total Debt Repaid | -186.71 | -187.31 | -181.25 | -168.68 | -156.18 | -149.84 | Upgrade
|
| Net Debt Issued (Repaid) | -186.71 | -187.31 | -181.25 | -168.68 | -156.18 | -149.84 | Upgrade
|
| Common Dividends Paid | -9,187 | -7,494 | -5,416 | -15,255 | -5,066 | -6,770 | Upgrade
|
| Other Financing Activities | -16.14 | -13.14 | -17.99 | -9.55 | -19.9 | -35.31 | Upgrade
|
| Financing Cash Flow | -9,390 | -7,694 | -5,615 | -15,433 | -5,242 | -6,956 | Upgrade
|
| Net Cash Flow | 2,907 | 4,747 | 292.3 | -2,512 | -1,190 | 3,004 | Upgrade
|
| Free Cash Flow | 7,191 | 12,669 | 5,508 | 4,402 | 7,761 | 5,337 | Upgrade
|
| Free Cash Flow Growth | -23.51% | 130.01% | 25.13% | -43.28% | 45.42% | 59.50% | Upgrade
|
| Free Cash Flow Margin | 19.39% | 33.79% | 15.95% | 13.54% | 23.68% | 18.24% | Upgrade
|
| Free Cash Flow Per Share | 42.45 | 74.78 | 32.51 | 25.98 | 45.81 | 31.50 | Upgrade
|
| Cash Interest Paid | 19.64 | 13.14 | 17.99 | 13.98 | 17.37 | 35.31 | Upgrade
|
| Cash Income Tax Paid | 2,834 | 823.79 | 2,349 | 2,646 | 1,195 | 1,474 | Upgrade
|
| Levered Free Cash Flow | 6,182 | 11,624 | 6,701 | 1,562 | 10,097 | 3,506 | Upgrade
|
| Unlevered Free Cash Flow | 6,192 | 11,632 | 6,712 | 1,573 | 10,109 | 3,528 | Upgrade
|
| Change in Working Capital | -1,963 | 1,848 | 610.21 | -457.46 | 1,199 | 457.46 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.